anastrozole + exemestane + letrozole + tamoxifen

This is a combination of four drugs used in the hormonal treatment of breast cancer, specifically estrogen receptor-positive (ER+) breast cancer. Anastrozole, exemestane, and letrozole are aromatase inhibitors that work by blocking the enzyme aromatase, thereby reducing estrogen production in postmenopausal women. Tamoxifen is a selective estrogen receptor modulator (SERM) that blocks the effects of estrogen on breast tissue. These agents are typically not used together simultaneously but may be sequenced or switched during therapy depending on patient response and tolerance. The primary indication for these drugs is hormone receptor-positive breast cancer in postmenopausal women[1][3][7].

Other names

Standard adjuvant endocrine therapySET